1921
Volume 87, Issue 1
  • ISSN: 0002-9637
  • E-ISSN: 1476-1645

Abstract

Abstract.

Antimalarials are widely used in African and Southeast Asian countries, where they are combined with other drugs for the treatment of concurrent ailments. The potential for P-glycoprotein (P-gp)-mediated drug-drug interactions (DDIs) between antimalarials and P-gp substrates was examined using a Caco-2 cell-based model. Selected antimalarials were initially screened for their interaction with P-gp based on the inhibition of rhodamine-123 (Rho-123) transport in Caco-2 cells. Verapamil (100 μM) and quinidine (1 μM) were used as positive inhibition controls. Lumefantrine, amodiaquin, and artesunate all showed blockade of Rho-123 transport. Subsequently, the inhibitory effect of these antimalarials on the bi-directional passage of digoxin (DIG) was examined. All of the drugs decreased basal-to-apical (B-A) P-gp-mediated DIG transport at concentrations of 100 μM and 1 mM. These concentrations may reflect therapeutic doses for amodiaquin and artesunate. Therefore, clinically relevant DDIs may occur between certain antimalarials and P-gp substrates in general.

Loading

Article metrics loading...

/content/journals/10.4269/ajtmh.2012.11-0817
2012-07-02
2017-09-24
Loading full text...

Full text loading...

/deliver/fulltext/14761645/87/1/64.html?itemId=/content/journals/10.4269/ajtmh.2012.11-0817&mimeType=html&fmt=ahah

References

  1. WHO, 2000. World Health Organization Expert Committee on Malaria. 20th Report, WHO, Geneva. Available at: http://www.rollbackmalaria.org/docs/ecr20.pdf. Accessed April 28, 2011.
  2. Breman JG, Alilio MS, Mills A, , 2004. Conquering the intolerable burden of malaria: what's new, what's needed: a summary. Am J Trop Med Hyg 71: 115.
  3. Hay SI, Guerra CA, Tatem AJ, Atkinson PM, Snow RW, , 2005. Urbanization, malaria transmission and disease burden in Africa. Nat Rev Microbiol 3: 8190.[Crossref]
  4. Brentlinger P, Behrens C, Mice M, , 2006. Challenges in the concurrent management of malaria and HIV in pregnancy in sub-Saharan Africa. Lancet Infect Dis 6: 100111.[Crossref]
  5. Fehintola FA, Akinyinka OO, Adewole IF, Maponga CC, Ma Q, Morse GD, , 2011. Drug interactions in the treatment and chemoprophylaxis of malaria in HIV infected individuals in sub Saharan Africa. Curr Drug Metab 12: 5156.[Crossref]
  6. Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L, , 2010. Membrane transporters in drug development. Nat Rev Drug Discov 9: 215236.[Crossref]
  7. Giacomini K, Sugiyama Y, Brunton LL, Lazo JS, Parker KL, , 2005. Membrane transporters and drug response. , eds. Goodman & Gilman's: The Pharmacological Basis of Therapeutics. New York: McGraw-Hill, 4170.
  8. Tanigawara Y, , 2000. Role of P-glycoprotein in drug disposition. Ther Drug Monit 22: 137140.[Crossref]
  9. Kato M, Shitara Y, Kitajima M, Tachibana T, Ishigai M, Horie T, Sugiyama Y, Pang KS, Rodrigues AD, Peter R, , 2010. Extrapolation of in vitro metabolic and P-glycoprotein-mediated transport data to in vivo by modeling and simulation. , eds. Enzyme-and Transporter-based Drug-Drug interactions, Progress and Future Challenges. New York: Springer, 299315.
  10. Tachibana T, Kato M, Watanabe T, Mitsui T, Sugiyama Y, , 2009. Method for predicting the risk of drug–drug interactions involving inhibition of intestinal CYP3A4 and P-glycoprotein. Xenobiotica 39: 430443.[Crossref]
  11. Rostami-Hodjegan A, Tucker G, , 2004. In silico simulations to assess the in vivo consequences of in vitro metabolic drug–drug interactions. Drug Discov Today Technol 1: 441448.[Crossref]
  12. Sugimoto H, Matsumoto S, Tachibana M, Niwa S, Hirabayashi H, Amano N, Moriwaki T, , 2011. Establishment of in vitro P-glycoprotein inhibition assay and its exclusion criteria to assess the risk of drug–drug interaction at the drug discovery stage. J Pharm Sci 100: 40134023.[Crossref]
  13. Cavet ME, West M, Simmons NL, , 1996. Transport and epithelial secretion of the cardiac glycoside, digoxin, by human intestinal epithelial (Caco-2) cells. Br J Pharmacol 118: 13891396.[Crossref]
  14. Lin JH, , 2007. Transporter-mediated drug interactions: clinical implications and in vitro assessment. Expert Opin Drug Metab Toxicol 3: 8192.[Crossref]
  15. Horn J, Hansten P, , 2004. Drug interactions with digoxin: the role of P-glycoprotein. Pharm Times October, 4546.
  16. Takano M, Hasegawa R, Fukuda T, Yumoto R, Nagai J, Murakami T, , 1998. Interaction with P-glycoprotein and transport of erythromycin, midazolam and ketoconazole in Caco-2 cells. Eur J Pharmacol 358: 289294.[Crossref]
  17. Artursson P, Palm K, Luthman K, , 2001. Caco-2 monolayers in experimental and theoretical predictions of drug transport. Adv Drug Deliv Rev 46: 2743.[Crossref]
  18. Dressman JB, Amidon GL, Reppas C, Shah VP, , 1998. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm Res 15: 1122.[Crossref]
  19. Hayeshi R, Masimirembwa C, Mukanganyama S, Ungell AL, , 2006. The potential inhibitory effect of antiparasitic drugs and natural products on P-glycoprotein mediated efflux. Eur J Pharm Sci 29: 7081.[Crossref]
  20. Reungpatthanaphong P, Mankhetkorn S, , 2002. Modulation of multidrug resistance by artemisinin, artesunate and dihydroartemisinin in K562/adr and GLC4/adr resistant cell lines. Biol Pharm Bull 25: 15551561.[Crossref]
  21. Zhang L, Zhang YD, Zhao P, Huang SM, , 2009. Predicting drug-drug interactions: an FDA perspective. AAPS J 11: 300306.[Crossref]
  22. Kim RB, Fromm MF, Wandel C, Leake B, Wood AJ, Roden DM, Wilkinson GR, , 1998. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest 101: 289294.[Crossref]
  23. Storch CH, Theile D, Lindenmaier H, Haefeli WE, Weiss J, , 2007. Comparison of the inhibitory activity of anti-HIV drugs on P-glycoprotein. Biochem Pharmacol 73: 15731581.[Crossref]
  24. Finkelstein Y, Aks SE, Hutson JR, Juurlink DN, Nguyen P, Dubnov-Raz G, Pollak U, Koren G, Bentur Y, , 2010. Colchicine poisoning: the dark side of an ancient drug. Clin Toxicol 48: 407414.[Crossref]
  25. Crowe A, Ilett KF, Karunajeewa HA, Batty KT, Davis TM, , 2006. Role of P glycoprotein in absorption of novel antimalarial drugs. Antimicrob Agents Chemother 50: 35043506.[Crossref]
  26. Pham YT, Regina A, Farinotti R, Couraud P, Wainer IW, Roux F, Gimenez F, , 2000. Interactions of racemic mefloquine and its enantiomers with P-glycoprotein in an immortalised rat brain capillary endothelial cell line, GPNT. Biochim Biophys Acta 1524: 212219.[Crossref]
  27. Qi J, Wang S, Liu G, Peng H, Wang J, Zhu Z, Yang C, , 2004. Pyronaridine, a novel modulator of P-glycoprotein-mediated multidrug resistance in tumor cells in vitro and in vivo . Biochem Biophys Res Commun 319: 11241131.[Crossref]
  28. WHO, 2010. Guidelines for the Treatment of Malaria. Second edition. Geneva: World Health Organization Press, 194.
  29. Price RN, Dorsey G, Ashley EA, Barnes KI, Baird JK, d'Alessandro U, Guerin PJ, Laufer MK, Naidoo I, Nosten F, Olliaro P, Plowe CV, Ringwald P, Sibley CH, Stepniewska K, White NJ, , 2007. World Antimalarial Resistance Network I: clinical efficacy of antimalarial drugs. Malar J 6: 119.[Crossref]
  30. Bacon DJ, Jambou R, Fandeur T, Le Bras J, Wongsrichanalai C, Fukuda MM, Ringwald P, Sibley CH, Kyle DE, , 2007. World Antimalarial Resistance Network (WARN) II: in vitro antimalarial drug susceptibility. Malar J 6: 120.[Crossref]
  31. Yeung S, Pongtavornpinyo W, Hastings IM, Mills AJ, White NJ, , 2004. Antimalarial drug resistance, artemisinin-based combination therapy, and the contribution of modeling to elucidating policy choices. Am J Trop Med Hyg 71: 179186.
  32. White NJ, , 2004. Antimalarial drug resistance. J Clin Invest 113: 10841092.[Crossref]
http://instance.metastore.ingenta.com/content/journals/10.4269/ajtmh.2012.11-0817
Loading
/content/journals/10.4269/ajtmh.2012.11-0817
Loading

Data & Media loading...

  • Received : 31 Dec 2011
  • Accepted : 31 Mar 2012

Most Cited This Month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error